Physician profile
Pamela C Stringer
NPI 1114624038
$2,651.62
in general payments reported to CMS, 2019-2025
20 companies · $911 in 2025
The $911 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $760 · 2024: $981 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,651.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $522.28 | 2023-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $420.12 | 2023-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $386.34 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $368.66 | 2023-2025 | Lifevest |
| Pfizer INC. | $179.49 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $169.18 | 2023-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $144.92 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.89 | 2023-2025 | Jardiance |
| Amgen INC. | $74.04 | 2023-2024 | Repatha |
| Scpharmaceuticals INC. | $62.54 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $50.14 | 2023-2024 | Inpefa |
| Cvrx, INC. | $28.76 | 2023-2024 | Barostim Neo System |
| Boston Scientific Corporation | $26.22 | 2023-2024 | Watchman Flx |
| Esperion Therapeutics, INC. | $23.68 | 2023 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $20.26 | 2024 | Arcalyst |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.80 | 2025 | |
| Glaxosmithkline, LLC. | $17.87 | 2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $15.37 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $15.07 | 2024 | Evkeeza |
| Bridgebio Pharma, INC. | $14.99 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Stringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.